Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Benjamin Rains headshot

Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?

Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...

Sheraz Mian headshot

Earnings Strength and Market Weakness

Market volatility notwithstanding, we have to acknowledge that the fundamental backdrop, as reflected in the outlook for earnings and interest rates, remains very favorable...

Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings

Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".

Personal Income Increased in December

Personal Income Increased in December

Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.

Mark Vickery headshot

Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data

With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates

J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.

Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?

Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $35.86, moving -1.05% from the previous trading session.

Mark Vickery headshot

Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets

The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.

Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Sweta Killa headshot

JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus

The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.

Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer

The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca

Pfizer (PFE) Gains As Market Dips: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $37.31, marking a +0.08% move from the previous day.

Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer

The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.

How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?

Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?

Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX

Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.

Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC

Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.

The Zacks Analyst Blog Highlights: Amazon, JPMorgan, Pfizer, Salesforce and Chevron

The Zacks Analyst Blog Highlights: Amazon, JPMorgan, Pfizer, Salesforce and Chevron

VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine

VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.

Sheraz Mian headshot

Q4 Earnings Season Scorecard and Analyst Reports for Amazon, JPMorgan & Pfizer

Today's Research Daily features an update on the Q4 earnings season and new research reports on Amazon.com (AMZN), JPMorgan Chase (JPM), Pfizer (PFE) and others.

Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan

Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.